Patient Resources & Learning
Trusted resources to help you understand giant cell arteritis (GCA), find support, and get help with treatment. These links go to outside organizations and are provided for your convenience. Always talk with your own care team about your diagnosis and treatment.
Sudden vision loss or change is an emergency
Go to the nearest emergency room right away. Early treatment can protect your sight.
Vasculitis Foundation
The Vasculitis Foundation is the leading patient organization for vasculitis, including GCA. It offers education, webinars, support groups, and opportunities to take part in research.
Learn more about GCA
- American College of Rheumatology — GCAPatient overview from the leading U.S. rheumatology society.
- American College of Rheumatology — Polymyalgia RheumaticaAbout PMR, a condition closely related to GCA.
- MedlinePlus (NIH) — Giant Cell ArteritisClear, plain-language information from the National Library of Medicine.
- NORD — Giant Cell ArteritisDetailed overview from the National Organization for Rare Disorders.
Medications for GCA
Treatment usually begins with corticosteroids (such as prednisone) to calm inflammation quickly and protect vision. Many patients also take a steroid-sparing medicine to control the disease and lower the total amount of steroids needed. Two medicines are FDA-approved specifically for GCA:
- Tocilizumab (Actemra)An interleukin-6 (IL-6) inhibitor given by injection. It can help control GCA and reduce steroid exposure.
- Upadacitinib (Rinvoq)An oral JAK inhibitor, FDA-approved for GCA in 2025 based on the SELECT-GCA trial.
A note about JAK inhibitors (like upadacitinib)
JAK inhibitors carry the FDA’s strongest (“boxed”) warning for serious infections, blood clots, certain cancers, and major cardiovascular events such as heart attack and stroke, as well as a higher risk of death. These risks come largely from a study of a different JAK inhibitor in people with rheumatoid arthritis who had heart-disease risk factors; in the giant cell arteritis trial, these cardiovascular events were not seen, but the warnings still apply to this class of medicines. Your rheumatologist will weigh these risks with you, especially if you have heart-disease risk factors, a history of blood clots or cancer, or you smoke. Read the FDA’s JAK-inhibitor warning.
Living with treatment: steroids & bone health
GCA is usually treated with corticosteroids (such as prednisone), sometimes for many months. Over time, steroids can weaken the bones, so it is worth asking your care team about protecting your bone health — including calcium and vitamin D, a bone-density (DEXA) scan, and whether a bone-protecting medication is right for you.
- Bone Health & Osteoporosis FoundationPatient information on protecting your bones, including during long-term steroid use.
Help paying for medication
If you are prescribed tocilizumab or upadacitinib and are worried about cost, the manufacturers run programs that may help with out-of-pocket expenses or provide the medicine at no cost for those who qualify. These are listed for your convenience and are not an endorsement — your care team and insurance plan can help you find the best option.
- Tocilizumab (Actemra) Access SolutionsPatient support for coverage, co-pay assistance, and the Genentech Patient Foundation (free medicine for those who qualify).
- Upadacitinib (Rinvoq) CompleteCo-pay savings for eligible commercially insured patients, plus myAbbVie Assist for those without coverage who qualify.
Questions to ask your doctor
If you’re being evaluated for GCA
- Could my symptoms be giant cell arteritis?
- Do I need treatment right away to protect my vision?
- What tests will I need — blood tests, vascular ultrasound, or a biopsy?
- If a test is negative, could I still have GCA?
- What should I do if I notice vision changes while we are sorting this out?
If you’ve been diagnosed with GCA
- What are the side effects of steroids, and how will we protect my bones?
- Is a steroid-sparing medicine (such as tocilizumab or upadacitinib) right for me?
- What are the risks and benefits of each treatment option?
- How long will I be on treatment, and how will we lower the steroids over time?
- What signs mean my disease might be flaring?
- Do I need monitoring for medication side effects, such as lab tests, infection risk, or heart-disease risk?
- What should I do if I notice any vision changes?
What to expect at your vascular ultrasound
A vascular ultrasound is painless and uses sound waves — there are no needles and no radiation. A trained sonographer applies a little gel and gently moves a small probe over the arteries at your temples, and sometimes your arms and neck, to look for signs of inflammation. The exam typically takes under an hour. Your care team will give you any specific instructions before your visit.
Vascular ultrasound for GCA is not available at every medical center — it requires specially trained sonographers. At the University of Washington, our sonographers have performed hundreds of temporal artery ultrasounds since the program began in 2017.
Importantly, a vascular ultrasound that does not show inflammation does not completely rule out GCA. Depending on your symptoms, your doctor may still recommend a temporal artery biopsy (a small sample of the temple artery) to help confirm the diagnosis.
Common terms
- Giant cell arteritis (GCA)Inflammation of medium and large arteries, most often around the temples and scalp.
- VasculitisInflammation of blood vessels.
- Temporal artery biopsyA small sample of the temple artery, used in some cases to confirm GCA.
- Vascular ultrasoundA painless scan that can show inflammation in the artery walls (the "halo sign").
- ESR and CRPBlood tests that measure inflammation. They can occasionally be normal in GCA.
- AIONAnterior ischemic optic neuropathy — the main cause of GCA-related vision loss.
- Polymyalgia rheumatica (PMR)A related condition causing shoulder and hip stiffness, especially in the morning.
- Corticosteroids (prednisone)The main initial treatment, used to calm the inflammation quickly.
- Tocilizumab (Actemra)A steroid-sparing biologic medicine (an IL-6 inhibitor) given by injection to help control GCA.
- Upadacitinib (Rinvoq)An oral JAK-inhibitor medicine, FDA-approved for GCA in 2025, used to help control the disease and reduce steroids.
- JAK inhibitorA type of medicine taken by mouth that lowers immune-system activity; upadacitinib is one example.
- FlareA return of disease activity after improvement.
En español
- MedlinePlus en español — Arteritis de células gigantesInformación clara y confiable de la Biblioteca Nacional de Medicina.
- Vasculitis FoundationOfrece materiales educativos seleccionados en español.